Open Access
Open access
Proceedings of the National Academy of Sciences of the United States of America, volume 117, issue 13, pages 7021-7029

Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents

Thiabaud Gregory 1
He Guangan 2
Sen Sajal 1
Shelton Kathryn A 3
BAZE WALLACE B. 3
Segura Luke 3
Alaniz Julie 1
Munoz Macias Ruben 1
Lyness Greg 4
Watts Alan B 4
Kim Hyun-Min 5
Lee Hyunseung 5
Cho Mi-Young 5
Hong Kwan Hee 5
Finch Rick 3
Siddik Zahid H. 2
Arambula Jonathan F 1, 6
Sessler Jonathan L. 1, 5
1
 
Department of Chemistry, University of Texas at Austin, Austin, TX 78712-1224;
2
 
Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX 77030;
3
 
Department of Comparative Medicine, MD Anderson Cancer Center, Bastrop, TX 78602;
4
 
Drug Dynamics Institute, College of Pharmacy, University of Texas at Austin, Austin, TX 78712-1224;
5
 
Research Center for Bioconvergence Analysis, Korea Basic Science Institute, Cheongju 28119, Korea;
6
 
OncoTEX Inc., Austin, TX 78701
Publication typeJournal Article
Publication date2020-03-16
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor11.1
ISSN00278424, 10916490
Multidisciplinary
Abstract
Significance

Currently, cisplatin, carboplatin, and oxaliplatin are the only platinum agents approved by the US Food and Drug Administration for use in therapeutic regimens. While effective in select cancers, their clinical utility remains limited by intrinsic or acquired resistance. This is attributed, in part, to poor drug tumor localization and uptake. Additionally, one of the more formidable mechanisms of platinum resistance involves dysfunction of the tumor suppressor p53. Lack of wild-type p53 activation can translate to a significant reduction in the 5-y survival rate compared with mutant p53 in some cancers. The inability to overcome p53 dysfunction in concert with the dose-limiting toxicities and poor tumor-specific drug delivery of Pt provides an incentive to develop agents as described in this report.

Citations by journals

1
2
3
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 3, 7.32%
Journal of Medicinal Chemistry
3 publications, 7.32%
Coordination Chemistry Reviews
Coordination Chemistry Reviews, 3, 7.32%
Coordination Chemistry Reviews
3 publications, 7.32%
Inorganic Chemistry Frontiers
Inorganic Chemistry Frontiers, 3, 7.32%
Inorganic Chemistry Frontiers
3 publications, 7.32%
Chem
Chem, 2, 4.88%
Chem
2 publications, 4.88%
Journal of the American Chemical Society
Journal of the American Chemical Society, 2, 4.88%
Journal of the American Chemical Society
2 publications, 4.88%
Chemical Society Reviews
Chemical Society Reviews, 2, 4.88%
Chemical Society Reviews
2 publications, 4.88%
Chemical Science
Chemical Science, 2, 4.88%
Chemical Science
2 publications, 4.88%
Dalton Transactions
Dalton Transactions, 2, 4.88%
Dalton Transactions
2 publications, 4.88%
ACS Applied Bio Materials
ACS Applied Bio Materials, 1, 2.44%
ACS Applied Bio Materials
1 publication, 2.44%
Bioscience Reports
Bioscience Reports, 1, 2.44%
Bioscience Reports
1 publication, 2.44%
Nature Communications
Nature Communications, 1, 2.44%
Nature Communications
1 publication, 2.44%
Communications Chemistry
Communications Chemistry, 1, 2.44%
Communications Chemistry
1 publication, 2.44%
Inorganic Chemistry
Inorganic Chemistry, 1, 2.44%
Inorganic Chemistry
1 publication, 2.44%
Journal of Controlled Release
Journal of Controlled Release, 1, 2.44%
Journal of Controlled Release
1 publication, 2.44%
Journal of Molecular Structure
Journal of Molecular Structure, 1, 2.44%
Journal of Molecular Structure
1 publication, 2.44%
Current Opinion in Chemical Biology
Current Opinion in Chemical Biology, 1, 2.44%
Current Opinion in Chemical Biology
1 publication, 2.44%
Angewandte Chemie
Angewandte Chemie, 1, 2.44%
Angewandte Chemie
1 publication, 2.44%
Angewandte Chemie - International Edition
Angewandte Chemie - International Edition, 1, 2.44%
Angewandte Chemie - International Edition
1 publication, 2.44%
ChemMedChem
ChemMedChem, 1, 2.44%
ChemMedChem
1 publication, 2.44%
Chemistry - A European Journal
Chemistry - A European Journal, 1, 2.44%
Chemistry - A European Journal
1 publication, 2.44%
Molecular Pharmaceutics
Molecular Pharmaceutics, 1, 2.44%
Molecular Pharmaceutics
1 publication, 2.44%
Chemical Communications
Chemical Communications, 1, 2.44%
Chemical Communications
1 publication, 2.44%
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, 1, 2.44%
Proceedings of the National Academy of Sciences of the United States of America
1 publication, 2.44%
Nanoscale
Nanoscale, 1, 2.44%
Nanoscale
1 publication, 2.44%
Science advances
Science advances, 1, 2.44%
Science advances
1 publication, 2.44%
ACS Sensors
ACS Sensors, 1, 2.44%
ACS Sensors
1 publication, 2.44%
Advanced healthcare materials
Advanced healthcare materials, 1, 2.44%
Advanced healthcare materials
1 publication, 2.44%
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B, 1, 2.44%
Acta Pharmaceutica Sinica B
1 publication, 2.44%
ACS Infectious Diseases
ACS Infectious Diseases, 1, 2.44%
ACS Infectious Diseases
1 publication, 2.44%
1
2
3

Citations by publishers

2
4
6
8
10
12
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 11, 26.83%
Royal Society of Chemistry (RSC)
11 publications, 26.83%
American Chemical Society (ACS)
American Chemical Society (ACS), 10, 24.39%
American Chemical Society (ACS)
10 publications, 24.39%
Elsevier
Elsevier, 9, 21.95%
Elsevier
9 publications, 21.95%
Wiley
Wiley, 5, 12.2%
Wiley
5 publications, 12.2%
Springer Nature
Springer Nature, 3, 7.32%
Springer Nature
3 publications, 7.32%
Proceedings of the National Academy of Sciences (PNAS)
Proceedings of the National Academy of Sciences (PNAS), 1, 2.44%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 2.44%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 1, 2.44%
American Association for the Advancement of Science (AAAS)
1 publication, 2.44%
2
4
6
8
10
12
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Thiabaud G. et al. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents // Proceedings of the National Academy of Sciences of the United States of America. 2020. Vol. 117. No. 13. pp. 7021-7029.
GOST all authors (up to 50) Copy
Thiabaud G., He G., Sen S., Shelton K. A., BAZE W. B., Segura L., Alaniz J., Munoz Macias R., Lyness G., Watts A. B., Kim H., Lee H., Cho M., Hong K. H., Finch R., Siddik Z. H., Arambula J. F., Sessler J. L. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents // Proceedings of the National Academy of Sciences of the United States of America. 2020. Vol. 117. No. 13. pp. 7021-7029.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1073/pnas.1914911117
UR - https://doi.org/10.1073%2Fpnas.1914911117
TI - Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents
T2 - Proceedings of the National Academy of Sciences of the United States of America
AU - Thiabaud, Gregory
AU - He, Guangan
AU - Sen, Sajal
AU - Shelton, Kathryn A
AU - BAZE, WALLACE B.
AU - Segura, Luke
AU - Alaniz, Julie
AU - Munoz Macias, Ruben
AU - Lyness, Greg
AU - Watts, Alan B
AU - Kim, Hyun-Min
AU - Lee, Hyunseung
AU - Cho, Mi-Young
AU - Hong, Kwan Hee
AU - Finch, Rick
AU - Siddik, Zahid H.
AU - Arambula, Jonathan F
AU - Sessler, Jonathan L.
PY - 2020
DA - 2020/03/16 00:00:00
PB - Proceedings of the National Academy of Sciences (PNAS)
SP - 7021-7029
IS - 13
VL - 117
PMID - 32179677
SN - 0027-8424
SN - 1091-6490
ER -
BibTex |
Cite this
BibTex Copy
@article{2020_Thiabaud
author = {Gregory Thiabaud and Guangan He and Sajal Sen and Kathryn A Shelton and WALLACE B. BAZE and Luke Segura and Julie Alaniz and Ruben Munoz Macias and Greg Lyness and Alan B Watts and Hyun-Min Kim and Hyunseung Lee and Mi-Young Cho and Kwan Hee Hong and Rick Finch and Zahid H. Siddik and Jonathan F Arambula and Jonathan L. Sessler},
title = {Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
year = {2020},
volume = {117},
publisher = {Proceedings of the National Academy of Sciences (PNAS)},
month = {mar},
url = {https://doi.org/10.1073%2Fpnas.1914911117},
number = {13},
pages = {7021--7029},
doi = {10.1073/pnas.1914911117}
}
MLA
Cite this
MLA Copy
Thiabaud, Gregory, et al. “Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.” Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 13, Mar. 2020, pp. 7021-7029. https://doi.org/10.1073%2Fpnas.1914911117.
Found error?